Navigation Links
Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society

DANBURY, Conn., July 6 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, U.S.A. next week.

Oral Presentation:

#51, Oral session on peptides and proteins, Monday July 12, 2010 4:00 PM (PT) "'Smart' Basal Insulin Formulation that Releases Insulin in Response to Blood Glucose Concentrations of Diabetic Swine," to be presented by N. Kashyap, Biodel Inc.

Poster Presentation:

#373, Poster session on peptides and proteins, Monday July 12, 2010 1:00 PM - 2:00 PM (PT) "Effect of EDTA Concentration on Ultra-Rapid Action of VIAject® in Diabetic Miniature Swine," to be presented by Dr. R. Pohl, Biodel Inc.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes.  Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs.  Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010.  Earlier-stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
2. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
3. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
4. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
6. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
7. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
8. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
9. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
10. Sysmex America Announces Executive Leadership Changes
11. FUISZ Announces Advances in Devices and Solid Dosage Form
Post Your Comments:
(Date:12/1/2015)... 1, 2015   MabVax Therapeutics Holdings, Inc . ... it has filed an Investigational New Drug Application (IND) ... the Company,s lead fully human antibody product HuMab 5B1 ... plans to initiate the Phase I clinical trial early ... --> The planned Phase I trial will evaluate ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Medical Alert Systems/Personal Emergency Response ... by Geography - Global Forecas" report to ... announced the addition of the "Medical Alert ... by End-User and by Geography - Global Forecas" ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... The Multiple System Atrophy Coalition has announced the launch of ... (MSA) research, timed today to coincide with Giving Tuesday 2015, a global day of ... to work and be productive, to do simple daily activities like walking to the ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... expansion of the company’s growing product line of food safety and seafood fraud ... Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):